Opthea is raising about $220 million to fund the ASX-listed biotech through to its phase-three read-out early next year, sources say.
The company, with a market capitalisation of $321 million was placed in a trading halt on Friday ahead of the capital raising, which is expected to be overseen by MST Financial.
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
